1-6 of 6
Joseph Tripodi, MS
Close
Save search
Sort by
Journal Articles

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

Free
Vesna Najfeld, PhD, Joseph Tripodi, MS, Xiaoli Wang, MD PhD, Myron Schwartz, MD, Marina Kremyanskaya, MDPhD, Edward Cytryn, Sharon Zirkiev, Raajit K. Rampal, MD, PhD, John O Mascarenhas, MD MS, Ronald Hoffman, MD
Journal: Blood
Blood (2014) 124 (21): 1871.
https://doi.org/10.1182/blood.V124.21.1871.1871
Published: 2014
Journal Articles

Peripheral Blood Karyotyping Is Superior To Bone Marrow and Identifies Most Frequent Structural Chromosomal Rearrangements In Myelofibrosis

Free
Vesna Najfeld, PhD, Joseph Tripodi, MS, Marina Kremanskaya, MD, John Mascarenhas, MD, Ronald Hoffman, MD
Journal: Blood
Blood (2013) 122 (21): 3727.
https://doi.org/10.1182/blood.V122.21.3727.3727
Published: 2013
Journal Articles

Characterization Of Splenic Fibroblasts From Patients With Myelofibrosis

Free
Xiaoli Wang, Joseph Tripodi, MS, Vesna Najfeld, PhD, Min Lu, PhD, Ronald Hoffman, MD
Journal: Blood
Blood (2013) 122 (21): 4107.
https://doi.org/10.1182/blood.V122.21.4107.4107
Published: 2013
Journal Articles

JAK2 Inhibitors Do Not Affect Stem Cells Present in the Spleens of Patients with Myelofibrosis

Free
Xiaoli Wang, MD, PhD, Joseph Tripodi, MS, Jesse Novak, Min Lu, PhD., Yan Li, Vesna Najfeld, Ph.D, Ronald Hoffman, MD
Journal: Blood
Blood (2012) 120 (21): 1752.
https://doi.org/10.1182/blood.V120.21.1752.1752
Published: 2012
Journal Articles

Chromosomal and FISH Study of 286 Patients with Primary Myelofibrosis (PMF) Reveals Cryptic Abnormalities and Identifies Lesions Associated with Favorable Prognosis and Disease Progression,

Free
Vesna Najfeld, PhD, John Mascarenhas, MD, Steven Fruchtman, MD, Samuel Cytryn, Marina Kremyanskaya, MD, Joseph Tripodi, MS, Ronald Hoffman, MD
Journal: Blood
Blood (2011) 118 (21): 3526.
https://doi.org/10.1182/blood.V118.21.3526.3526
Published: 2011
Journal Articles

Treatment with Nutlin-3, a Small-Molecule Antagonist of MDM2, in Combination with Low Doses of Pegylated Interferon Alpha 2a Targets Hematopoietic Progenitor Cells From Polycythemia Vera (PV) Patients

Free
Min Lu, PhD, Joseph Tripodi, MS, Yan Li, Xiaoli Wang, MD, PhD, Vesna Najfeld, PhD, John Mascarenhas, MD, Ronald Hoffman, MD
Journal: Blood
Blood (2011) 118 (21): 796.
https://doi.org/10.1182/blood.V118.21.796.796
Published: 2011